Logo image of ABVX

ABIVAX SA-ADR (ABVX) Stock Price, Quote, News and Overview

NASDAQ:ABVX - Nasdaq - US00370M1036 - ADR - Currency: USD

70.83  +1.03 (+1.48%)

After market: 69.9 -0.93 (-1.31%)

ABVX Quote, Performance and Key Statistics

ABIVAX SA-ADR

NASDAQ:ABVX (7/30/2025, 6:44:25 PM)

After market: 69.9 -0.93 (-1.31%)

70.83

+1.03 (+1.48%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High72.9
52 Week Low4.77
Market Cap4.50B
Shares63.47M
Float58.18M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)09-08 2025-09-08
IPO06-26 2015-06-26


ABVX short term performance overview.The bars show the price performance of ABVX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 200 400 600 800 1K

ABVX long term performance overview.The bars show the price performance of ABVX in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300 400

The current stock price of ABVX is 70.83 USD. In the past month the price increased by 824.67%. In the past year, price increased by 491.77%.

ABIVAX SA-ADR / ABVX Daily stock chart

ABVX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.43 334.40B
AMGN AMGEN INC 14.52 162.05B
GILD GILEAD SCIENCES INC 14.83 142.75B
VRTX VERTEX PHARMACEUTICALS INC N/A 120.48B
REGN REGENERON PHARMACEUTICALS 12.52 59.88B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 44.31B
ARGX ARGENX SE - ADR 104.34 36.65B
ONC BEONE MEDICINES LTD-ADR 7.67 32.46B
BNTX BIONTECH SE-ADR N/A 26.46B
INSM INSMED INC N/A 19.95B
SMMT SUMMIT THERAPEUTICS INC N/A 19.80B
NTRA NATERA INC N/A 19.25B

About ABVX

Company Profile

ABVX logo image Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 67 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Company Info

ABIVAX SA-ADR

7-11 Boulevard Haussmann

Paris ILE-DE-FRANCE FR

Employees: 67

ABVX Company Website

ABVX Investor Relations

Phone: 33153830963

ABIVAX SA-ADR / ABVX FAQ

What is the stock price of ABIVAX SA-ADR today?

The current stock price of ABVX is 70.83 USD. The price increased by 1.48% in the last trading session.


What is the ticker symbol for ABIVAX SA-ADR stock?

The exchange symbol of ABIVAX SA-ADR is ABVX and it is listed on the Nasdaq exchange.


On which exchange is ABVX stock listed?

ABVX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ABIVAX SA-ADR stock?

13 analysts have analysed ABVX and the average price target is 31.51 USD. This implies a price decrease of -55.51% is expected in the next year compared to the current price of 70.83. Check the ABIVAX SA-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ABIVAX SA-ADR worth?

ABIVAX SA-ADR (ABVX) has a market capitalization of 4.50B USD. This makes ABVX a Mid Cap stock.


How many employees does ABIVAX SA-ADR have?

ABIVAX SA-ADR (ABVX) currently has 67 employees.


Is ABIVAX SA-ADR (ABVX) expected to grow?

The Revenue of ABIVAX SA-ADR (ABVX) is expected to grow by 588.98% in the next year. Check the estimates tab for more information on the ABVX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ABIVAX SA-ADR (ABVX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ABIVAX SA-ADR (ABVX) stock pay dividends?

ABVX does not pay a dividend.


When does ABIVAX SA-ADR (ABVX) report earnings?

ABIVAX SA-ADR (ABVX) will report earnings on 2025-09-08.


What is the Price/Earnings (PE) ratio of ABIVAX SA-ADR (ABVX)?

ABIVAX SA-ADR (ABVX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.21).


What is the Short Interest ratio of ABIVAX SA-ADR (ABVX) stock?

The outstanding short interest for ABIVAX SA-ADR (ABVX) is 2.45% of its float. Check the ownership tab for more information on the ABVX short interest.


ABVX Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to ABVX. When comparing the yearly performance of all stocks, ABVX is one of the better performing stocks in the market, outperforming 99.8% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ABVX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ABVX. Both the profitability and financial health of ABVX have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ABVX Financial Highlights

Over the last trailing twelve months ABVX reported a non-GAAP Earnings per Share(EPS) of -3.21. The EPS increased by 16.74% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -85.88%
ROE -434.26%
Debt/Equity 1.29
Chartmill High Growth Momentum
EPS Q2Q%21.47%
Sales Q2Q%N/A
EPS 1Y (TTM)16.74%
Revenue 1Y (TTM)N/A

ABVX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 88% to ABVX. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of -4.62% and a revenue growth 588.98% for ABVX


Ownership
Inst Owners42.26%
Ins OwnersN/A
Short Float %2.45%
Short Ratio1.08
Analysts
Analysts87.69
Price Target31.51 (-55.51%)
EPS Next Y-4.62%
Revenue Next Year588.98%